0OT Stock Overview
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ocular Therapeutix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.03 |
| 52 Week High | US$10.81 |
| 52 Week Low | US$1.88 |
| Beta | 1.32 |
| 1 Month Change | -53.51% |
| 3 Month Change | -0.74% |
| 1 Year Change | -24.89% |
| 3 Year Change | -74.19% |
| 5 Year Change | 22.30% |
| Change since IPO | -57.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0OT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -34.2% | 2.3% | 0.5% |
| 1Y | -24.9% | -28.6% | 1.3% |
Price Volatility
| 0OT volatility | |
|---|---|
| 0OT Average Weekly Movement | 16.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0OT's share price has been volatile over the past 3 months.
Volatility Over Time: 0OT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 267 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix, Inc. Fundamentals Summary
| 0OT fundamental statistics | |
|---|---|
| Market cap | €669.88m |
| Earnings (TTM) | -€75.26m |
| Revenue (TTM) | €54.48m |
12.3x
P/S Ratio-8.9x
P/E RatioIs 0OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0OT income statement (TTM) | |
|---|---|
| Revenue | US$58.44m |
| Cost of Revenue | US$66.34m |
| Gross Profit | -US$7.89m |
| Other Expenses | US$72.84m |
| Earnings | -US$80.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -13.51% |
| Net Profit Margin | -138.14% |
| Debt/Equity Ratio | 82.2% |
How did 0OT perform over the long term?
See historical performance and comparison